[go: up one dir, main page]

MX2009006764A - Pirimidinonas biciclicas y usos de la misma. - Google Patents

Pirimidinonas biciclicas y usos de la misma.

Info

Publication number
MX2009006764A
MX2009006764A MX2009006764A MX2009006764A MX2009006764A MX 2009006764 A MX2009006764 A MX 2009006764A MX 2009006764 A MX2009006764 A MX 2009006764A MX 2009006764 A MX2009006764 A MX 2009006764A MX 2009006764 A MX2009006764 A MX 2009006764A
Authority
MX
Mexico
Prior art keywords
formula
prodrug
salt
subject
compound
Prior art date
Application number
MX2009006764A
Other languages
English (en)
Inventor
Jonathan Alan Victor Coates
Eric Dale Jones
David Ian Rhodes
John Joseph Deadman
Nicholas Andrew Vandegraff
Lisa Jane Winfield
Neeranat Thienthong
William Issa
Neil Choi
Katherine Macfarlane
Original Assignee
Avexa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907283A external-priority patent/AU2006907283A0/en
Application filed by Avexa Ltd filed Critical Avexa Ltd
Publication of MX2009006764A publication Critical patent/MX2009006764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula I o un derivado, sal o profármaco farmacéuticamente aceptable del mismo. Se proporciona además un método de tratamiento o profilaxis contra una infección viral en un sujeto, comprendiendo administrarle al sujeto en cuestión una cantidad efectiva de un compuesto de la Fórmula I o un derivado, sal o profármaco farmacéuticamente aceptable del mismo. También se proporciona una composición farmacéutica o el medicamento que comprende un compuesto de la Fórmula I.
MX2009006764A 2006-12-22 2007-12-21 Pirimidinonas biciclicas y usos de la misma. MX2009006764A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2006907283A AU2006907283A0 (en) 2006-12-22 Bicyclic pyrimidinones and uses thereof
AU2007902479A AU2007902479A0 (en) 2007-05-09 Bicyclic pyrimidinones and uses thereof (2)
AU2007903401A AU2007903401A0 (en) 2007-06-25 Bicyclic pyrimidinodes and uses thereof (3)
AU2007904114A AU2007904114A0 (en) 2007-07-31 Bicyclic pyrimidinones and uses thereof (4)
PCT/AU2007/001980 WO2008077188A1 (en) 2006-12-22 2007-12-21 Bicyclic pyrimidinones and uses thereof

Publications (1)

Publication Number Publication Date
MX2009006764A true MX2009006764A (es) 2009-11-26

Family

ID=39562030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006764A MX2009006764A (es) 2006-12-22 2007-12-21 Pirimidinonas biciclicas y usos de la misma.

Country Status (15)

Country Link
US (3) US8143268B2 (es)
EP (2) EP2269992A1 (es)
JP (2) JP5208962B2 (es)
KR (2) KR20100049698A (es)
CN (1) CN101880280B (es)
AR (2) AR064517A1 (es)
AT (1) ATE496898T1 (es)
AU (2) AU2007336703B9 (es)
BR (2) BRPI0720564A2 (es)
CA (1) CA2673183C (es)
DE (1) DE602007012308D1 (es)
DK (1) DK2114903T3 (es)
MX (1) MX2009006764A (es)
NZ (1) NZ577491A (es)
WO (1) WO2008077188A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000031A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Imidazopyrimidinones and uses thereof
MX2011000149A (es) * 2008-07-02 2011-02-24 Avexa Ltd Compuestos que tienen propiedades antivirales.
PL2247601T3 (pl) * 2008-07-02 2013-09-30 Avexa Ltd Tiazopirymidynony i ich zastosowanie
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
WO2015038655A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
CN107531717B (zh) 2015-03-11 2021-07-27 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN108697709A (zh) 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN111065626B (zh) 2017-06-05 2024-09-27 Ptc医疗公司 用于治疗亨廷顿氏舞蹈病的化合物
EP3638318A4 (en) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. RNA SPLICE MODIFICATION PROCESSES
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
SG11202009212WA (en) 2018-03-27 2020-10-29 Ptc Therapeutics Inc Compounds for treating huntington's disease
CN112805280B (zh) 2018-06-27 2024-12-06 Ptc医疗公司 用于治疗亨廷顿氏病的杂芳基化合物
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL293340A (en) 2019-12-02 2022-07-01 Storm Therapeutics Ltd Polyheterocyclic compounds as mettl3 inhibitors
US12070445B2 (en) * 2021-08-27 2024-08-27 Wisconsin Alumni Research Foundation System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762186B2 (en) 2000-09-20 2004-07-13 Schering Corporation Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
PE20040840A1 (es) 2002-11-20 2004-12-30 Japan Tobacco Inc Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih
RU2379302C2 (ru) 2003-12-18 2010-01-20 Тиботек Фармасьютикалз Лтд. Аминобензимидазолы и бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
AU2006228278C1 (en) * 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
WO2007039218A1 (en) * 2005-10-04 2007-04-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors

Also Published As

Publication number Publication date
US8207334B2 (en) 2012-06-26
WO2008077188A1 (en) 2008-07-03
EP2114903B1 (en) 2011-01-26
CN101880280B (zh) 2014-07-16
AU2007336703B9 (en) 2014-03-27
EP2114903A4 (en) 2009-12-30
ATE496898T1 (de) 2011-02-15
NZ577491A (en) 2011-06-30
DE602007012308D1 (de) 2011-03-10
AR077043A2 (es) 2011-07-27
BRPI0720564A2 (pt) 2011-08-16
CN101880280A (zh) 2010-11-10
AU2007336703B2 (en) 2012-04-12
AU2010201160A1 (en) 2010-04-15
CA2673183C (en) 2014-06-10
JP2010222370A (ja) 2010-10-07
US20120232035A1 (en) 2012-09-13
CA2673183A1 (en) 2008-07-03
EP2269992A1 (en) 2011-01-05
US8143268B2 (en) 2012-03-27
US8859563B2 (en) 2014-10-14
AR064517A1 (es) 2009-04-08
JP5208962B2 (ja) 2013-06-12
US20100168063A1 (en) 2010-07-01
AU2007336703A1 (en) 2008-07-03
DK2114903T3 (da) 2011-04-18
EP2114903A1 (en) 2009-11-11
HK1131615A1 (en) 2010-01-29
KR20100049698A (ko) 2010-05-12
KR20090097194A (ko) 2009-09-15
US20110009366A1 (en) 2011-01-13
BRPI0722411A2 (pt) 2012-06-05
JP2010513322A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
MX2009006764A (es) Pirimidinonas biciclicas y usos de la misma.
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
GB0612423D0 (en) Therapeutic agents
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
JO2848B1 (en) Organic compounds
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
EP2039686A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND THEIR USES IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF ANTIVIRAL DISEASES
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
TW200806299A (en) Treatment of pain
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
MY165117A (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
NZ619259A (en) Inhibitors of influenza viruses replication
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX2010008921A (es) Derivados de oxazolidinona.
PH12014500386A1 (en) Combination treatment for hepatitis c
IN2012DN02502A (es)
WO2008009210A8 (fr) Composés de dihydropyrimidine optiquement purs et leurs utilisations dans la fabrication d'un médicament pour traiter ou prévenir des viroses
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
NZ600912A (en) Topical use of hydroxytyrosol and derivatives for the prevention of hiv infection
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2007013624A (es) Inhibidores de proteina cinasa.

Legal Events

Date Code Title Description
FG Grant or registration